[The prognostic significance of determining androgen receptors in prostatic cancer].
The role of androgen receptors (ARs) registration in cytosol tumor fraction has been investigated in 86 new cases of prostatic cancer. The frequency of occurrence and mean ARs levels in the tumor were found dependent on the disease stage and tumor differentiation. Well-differentiated against moderately and poorly differentiated prostatic cancers contain ARs in 73% and 39% of cases, respectively, in concentrations 10-100 fmol/mg protein and 100 fmol/mg protein, respectively. Patients with well-differentiated prostatic cancer at stage T1-4N0M0 and 10-100 fmol/mg protein ARs in the tumor tend to achieve longer remissions compared to patients with ARs-free tumors or tumor comprising ARs in concentrations surpassing 100 fmol/mg protein. No significant correlation exists between remission duration in patients on radiation treatment combined with estrogen therapy and the presence, levels of ARs in the tumor.
Kushlinskiĭ
N E
NE
Bassalyk
L S
LS
Svetozarskiĭ
N L
NL
Matveev
B P
BP
Gorilovskiĭ
L M
LM
Makarova
G V
GV
Bukharkin
B V
BV
Shakhov
E V
EV
Kliuchikhin
O Z
OZ
D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D003600:Cytosol / Q000737:chemistry; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011467:Prostate / Q000737:chemistry; D011471:Prostatic Neoplasms / Q000737:chemistry* / Q000473:pathology / Q000628:therapy; D011944:Receptors, Androgen / Q000032:analysis*; D012074:Remission Induction; D013997:Time Factors
D011944:Receptors, Androgen
Prognosticheskoe znachenie opredeleniia retseptorov androgenov pri rake predstatel'noĭ zhelezy.